M Gilson

Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

Sumita Khatri, Wendy C. Moore, Peter G. Gibson et al. · Journal of Allergy and Clinical Immunology · 2018 · 300 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study

Njira Lugogo, Christian Domingo, Pascal Chanez et al. · Clinical Therapeutics · 2016 · 278 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial

Florence Roufosse, Jean‐Emmanuel Kahn, Marc E. Rothenberg et al. · Journal of Allergy and Clinical Immunology · 2020 · 202 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +13

Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study

Sandhya Khurana, Guy Brusselle, Elisabeth H. Bel et al. · Clinical Therapeutics · 2019 · 166 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Stopping<i>versus</i>continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)

Wendy C. Moore, Oliver Kornmann, Marc Humbert et al. · European Respiratory Journal · 2021 · 117 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15